Emerging evidence has suggested a potential pathological association between early-onset left-sided colorectal cancer (EOLCC) and metabolic syndrome (MetS). However, the underlying genetic and molecular mechanisms remain insufficiently elucidated. This study aimed to identify and characterize key biomarkers associated with the progression and treatment response of MetS-related EOLCC. An in-hospital cohort was utilized to assess the clinical implications of primary tumor location in early-onset colorectal cancer (EOCRC). Differentially expressed genes (DEGs) and weighted gene coexpression network analysis (WGCNA) were employed to identify genes potentially associated with MetS-related EOLCC. Functional enrichment analyses were conducted to explore the underlying mechanisms. Candidate biomarkers were screened using random forest (RF) and support vector machine-recursive feature elimination (SVM-RFE) algorithms. Survival relevance, expression profiles, and diagnostic performance were analyzed to identify key biomarkers. Treatment responses were evaluated, and potential therapeutic compounds were identified through molecular docking. Single-cell RNA sequencing (scRNA-seq) data and in vitro experiments were used to validate gene expression and functional characteristics. The in-hospital cohort revealed a higher proportion of EOLCC among EOCRC patients. Using the edgeR package and WGCNA, we identified coexpressed genes common to both EOLCC and MetS, significantly enriched in pathways associated with stromal remodeling and metabolic regulation. Machine learning algorithms highlighted three candidate biomarkers. Among them, only CD151 was associated with prognosis and advanced disease stage. CD151 was strongly correlated with stromal remodeling and chemoresistance. Additionally, potential therapeutic compounds targeting MetS-related EOLCC were identified via molecular docking. scRNA-seq analysis confirmed the expression and functional patterns of CD151, particularly in tumor cells. The bioinformatics results were further validated through quantitative real-time PCR (qRT-PCR), western blotting, and immunohistochemical (IHC) staining. This study identified CD151 as a key biomarker in MetS-related EOLCC, offering valuable insights into prognosis, tumor biology, and personalized treatment strategies. CD151 may serve as a reference for future research and clinical applications targeting this disease subtype.
Recent studies have increasingly emphasized the poorer survival outcomes and reduced treatment responses associated with right-sided colon cancer (RCC). However, the underlying molecular mechanisms remain poorly understood. This study aimed to identify and characterize key biomarkers associated with progression and treatment response in patients with RCC. Primary location-related genes (PLGs), including MX1, were identified through weighted gene coexpression network analysis (WGCNA) to construct a primary location signature prognostic risk score (PLriskScore) in the TCGA RCC dataset. The prognostic performance of PLriskScore was validated using four GEO datasets. Tumor microenvironment scores and chemotherapy responses across PLriskScore subgroups were assessed in bulk RNA sequencing datasets. The key target gene was then identified using machine learning algorithms. Its expression and functional roles were examined in single-cell RNA sequencing (scRNA-seq) datasets. Expression patterns were validated by quantitative real-time PCR (qRT-PCR) and immunohistochemical (IHC) staining of clinical samples, while functional characteristics were confirmed using Cell Counting Kit-8 (CCK-8) and transwell migration assays. Seven PLGs (MX1, MLLT6, PEDS1, STK4, TOMM34, SLC35A2, and LZTS3) were used to establish the PLriskScore. A higher PLriskScore was significantly associated with poorer prognosis, advanced TNM stages, and increased stromal scores. Notably, the VEGF pathway was enriched in the high-PLriskScore group. Machine learning algorithms identified MX1 as a novel key target, closely related to chemoresistance and tumor microenvironment dysregulation. scRNA-seq analyses revealed that MX1 was predominantly expressed in epithelial cells and promoted angiogenesis through interactions with endothelial cells via the VEGFA-VEGFR2 pathway. Finally, in vitro experiments demonstrated that MX1 was highly expressed in RCC and enhanced proliferation and migration in two CRC cell lines. A prognostic model based on primary location-related genes was developed to predict prognosis and chemotherapy response in RCC. MX1 was identified as a pivotal target that promotes angiogenesis and chemoresistance, thereby providing a potential therapeutic strategy for patients with RCC.